Trebananib
As of the edition of 20 October 2026, Trebananib is a drug: stopped in 2014; acts on ANGPT1 and ANGPT2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2014
- Kind
- Unknown
- Registered trials
- 29, 1 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Hormones; Skin and connective tissue; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 12 | 12 | 0 | 0 |
| Phase 2 | 16 | 13 | 1 | 1 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 29 |